AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Lineage Cell Therapeutics Partners with William Demant Invest to Develop ReSonance for Hearing Loss
ByAinvest
Wednesday, Aug 27, 2025 2:13 am ET1min read
Lineage Cell Therapeutics has entered a research collaboration with William Demant Invest to develop ReSonance, a treatment for hearing loss. The collaboration will cover preclinical development activities, including cell manufacturing and regulatory strategy. WDI will fund up to $12 million in research collaboration costs over the multi-year period. This collaboration aims to advance Lineage's auditory neuronal cell transplant, ANP1, and potentially support an IND/CTA filing.
Lineage Cell Therapeutics, Inc. (LCTX) has entered into a research collaboration with William Demant Invest A/S (WDI) to advance the development of ReSonance, an auditory neuronal cell transplant for the treatment of hearing loss. The multi-year collaboration, which includes an investment from WDI, will focus on preclinical development activities such as cell manufacturing, proof-of-concept studies, translational/functional models, delivery development, outcome measures, regulatory strategy, and market analysis. The goal is to support a potential IND/CTA filing for the therapy.WDI will fund up to $12 million in research collaboration costs over the period, with development activities jointly conducted and managed by Lineage and scientists from Eriksholm Research Centre, part of Oticon A/S, a subsidiary of the Demant Group. The collaboration highlights Lineage's technology platform and the efficiency of its approach in advancing the ANP1 product concept through successful cell manufacturing and initial preclinical testing.
The partnership aims to integrate the hearing loss research expertise of Eriksholm Research Centre with Lineage's manufacturing and cell transplant expertise to explore the potential of a differentiated cell transplant and position the therapy for initial clinical development. According to the World Health Organization (WHO), nearly 2.5 billion people are expected to experience some degree of hearing loss by 2025, making this collaboration a significant step in addressing an unmet medical need.
References:
[1] https://www.marketscreener.com/news/lineage-cell-therapeutics-inc-announces-research-collaboration-with-william-demant-invest-to-devel-ce7c50ded98bf621
[2] https://www.businesswire.com/news/home/20250826289327/en/Lineage-Announces-Research-Collaboration-With-William-Demant-Invest-to-Develop-ReSonance-ANP1-for-Hearing-Loss
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet